New drug combo targets brain tumor growth
NCT ID NCT05798507
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early trial tests two oral drugs, defactinib and VS-6766, in 14 people with glioblastoma. The goal is to see how much drug reaches the brain tumor and check for side effects. Both drugs block different growth pathways that help glioblastoma cells grow. This study only looks at safety and drug levels, not whether the drugs shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Defactinib and avutometinib (VS-6766)
What this could lead to
If successful, this could point toward a new treatment approach for glioblastoma by targeting growth pathways in tumor cells.
What could go wrong
This is a very early, small study (14 people) focused on safety and drug levels, not effectiveness. The drugs may not reach enough of the tumor or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States